Akèy › Gliyòm › North Carolina
Etid klinik pou Gliyòm nan North Carolina
16 etid pou Gliyòm ap chèche patisipan nan sit nan North Carolina.
Vil nan North Carolina
Tèks ofisyèl etid la (Anglè)
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Novant Health Presbyterian Medical Center, Charlotte
- East Carolina University, Greenville
- Wake Forest University Health Sciences, Winston-Salem
Ap rekriteFaz 1/2
12 Months – 21 Years · Tout sèks · Mizajou Oct 1, 2026 · NCT05099003A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Levine Children's Hospital- Pediatric Neuro-Oncology, Charlotte
Ap rekriteFaz 1/2
Jiska laj 25 · Tout sèks · Mizajou Sep 25, 2026 · NCT04094610ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Duke University Medical Center, Durham
Ap rekriteFaz 2
12 Months – 39 Years · Tout sèks · Mizajou Sep 21, 2026 · NCT06838676Targeted Pediatric High-Grade Glioma Therapy
- Duke University Health System, Durham
Ap rekriteEtid obsèvasyon
12 Months – 39 Years · Tout sèks · Mizajou Sep 8, 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Duke University Health System, Durham
Ap rekriteFaz 2
Laj 12 a 39 · Tout sèks · Mizajou Sep 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT05303519ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
- Duke University Medical Center, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT05609994PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Duke Cancer Center, Durham
Ap rekriteFaz 2
Laj 3 a 39 · Tout sèks · Mizajou Aug 24, 2026 · NCT05096481MRI in High-Grade Glioma Patients Undergoing Chemoradiation
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05212272A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center, Winston-Salem
Ap rekriteFaz 2
Laj 8 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT05503797Lerapolturev (PVSRIPO) in GBM
- Duke University Medical Center, Durham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 20, 2026 · NCT06177964Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Duke University Health System, Durham
Ap rekriteFaz 1 bonèVolontè an sante akeyi
Laj 1 a 21 · Tout sèks · Mizajou Jun 29, 2026 · NCT06333899Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
- Duke University Medical Center, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT04547777Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Duke University Health System, Durham
Ap rekriteFaz 2
12 Months – 39 Years · Tout sèks · Mizajou May 29, 2026 · NCT05843253Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
- Duke University, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT06126744A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Duke University Health System, Durham
Ap rekriteFaz 1 bonè
Jiska laj 21 · Tout sèks · Mizajou Mar 18, 2026 · NCT04655404Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.